|
|
|
Volumn 24, Issue 3, 2010, Pages 197-
|
|
Single-tablet Quad regimen achieves high rate of virologic suppression.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ATAZANAVIR;
CYTOCHROME P450 3A;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ELVITEGRAVIR;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
OLIGOPEPTIDE;
ORGANOPHOSPHORUS COMPOUND;
OXAZINE DERIVATIVE;
PHOSPHONIC ACID DERIVATIVE;
PYRIDINE DERIVATIVE;
QUINOLONE DERIVATIVE;
RITONAVIR;
CD4 LYMPHOCYTE COUNT;
DOUBLE BLIND PROCEDURE;
DRUG ANTAGONISM;
DRUG COMBINATION;
DRUG EFFECT;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MULTICENTER STUDY;
NOTE;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
VIROLOGY;
VIRUS LOAD;
ADENINE;
ANTI-HIV AGENTS;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIALS, PHASE II AS TOPIC;
CYTOCHROME P-450 CYP3A;
DEOXYCYTIDINE;
DOUBLE-BLIND METHOD;
DRUG COMBINATIONS;
DRUG THERAPY, COMBINATION;
HIV INFECTIONS;
HIV-1;
HUMANS;
MULTICENTER STUDIES AS TOPIC;
OLIGOPEPTIDES;
ORGANOPHOSPHORUS COMPOUNDS;
OXAZINES;
PHOSPHONIC ACIDS;
PYRIDINES;
QUINOLONES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RITONAVIR;
TREATMENT OUTCOME;
VIRAL LOAD;
|
|
EID: 77954069487
PISSN: None
EISSN: 15577449
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|